ECONOMIC BURDEN OF HERPES ZOSTER IN SPAIN
Author(s)
Díez-Domingo J1, Ordobás M2, Curran D3, Matthews S4, Cambronero Md5, García-Martínez JA5, Morano R5
1FISABIO Public Health, Valencia, Spain, 2Epidemiology Department, Public Health Madrid, Madrid, Spain, 3GSK, Wavre, Belgium, 4Freelance on behalf of GSK, Wavre, Belgium, 5GSK, Madrid, Spain
OBJECTIVES: Herpes zoster (HZ) and its complications, including post-herpetic neuralgia (PHN), is a severe and painful disease, mainly observed in people ≥50 years old. The economic burden of HZ in Spain is not well documented, with only isolated regional data available. The aim of the study was to estimate HZ-related healthcare resources utilization and costs in Spanish adults ≥50 years. METHODS: A prospective, observational study was performed using surveillance networks in 3 regions in Spain (Madrid, Valencia and Cataluña). HZ cases in adults ≥50 were recruited, stratified by age group, through primary care centers. Both payer and societal perspectives were considered in the costs calculated during the 3 months following HZ rash onset or up to 9 months for PHN. Unit costs were taken from regional healthcare services tariffs and medication costs from public pharmacist’s retail prices. The costs associated with working days lost were evaluated by multiplying number of days lost by the average daily earnings from National Statistics Institute 2014. RESULTS: CONCLUSIONS: HZ and PHN have an important economic burden both for payers and society in general. Any intervention preventing HZ could contribute to avoid considerable costs in Spain.
Conference/Value in Health Info
2017-11, ISPOR Europe 2017, Glasgow, Scotland
Value in Health, Vol. 20, No. 9 (October 2017)
Code
PIN39
Topic
Economic Evaluation
Topic Subcategory
Cost/Cost of Illness/Resource Use Studies
Disease
Infectious Disease (non-vaccine)